Medtronic Achieves Highest Revenue Growth in a Decade

Medtronic plc, a global leader in healthcare technology, announced impressive financial results for its third quarter of fiscal year 2026, which concluded on January 23, 2026. The company reported worldwide revenue reaching $9.017 billion, marking an increase of 8.7% compared to the same period last year. This growth is particularly notable as it represents the highest enterprise revenue growth for Medtronic in ten quarters.

Geoff Martha, chairman and chief executive officer of Medtronic, expressed confidence in the company’s performance, stating, “Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio.” This success stems from strategic investments in high-growth opportunities and the expansion into new markets, which are expected to sustain long-term growth.

Financial Highlights

In terms of profitability, Medtronic’s GAAP operating profit for Q3 was $1.464 billion, with an operating margin of 16.2%. Non-GAAP figures were even stronger, with an operating profit of $2.177 billion and a margin of 24.1%. The net income for the quarter stood at $1.143 billion, translating to diluted earnings per share (EPS) of $0.89. Non-GAAP net income and diluted EPS were reported at $1.750 billion and $1.36, respectively.

Medtronic’s product segments showed varied performance. The cardiovascular portfolio experienced robust growth, up 11% year-over-year, with the Cardiac Ablation Solutions segment soaring by an extraordinary 80% due to the success of its pulsed field ablation portfolio. This reflects the company’s emphasis on innovation and technology development.

Future Guidance

Looking ahead, Medtronic reaffirmed its guidance for fiscal year 2026, projecting an organic revenue growth of approximately 5.5%. The company also anticipates diluted non-GAAP EPS in the range of $5.62 to $5.66, which includes a potential tariff impact of around $185 million. Excluding this impact, the projected growth for diluted non-GAAP EPS is estimated at 4.5%.

Thierry Piéton, Medtronic’s chief financial officer, highlighted the company’s commitment to investing in research and development to enhance its innovation pipeline. “This quarter, we again delivered accelerated growth while investing decisively in our future,” he stated. The company’s strategic focus on mergers and acquisitions has also been a key component of its growth strategy, with two significant transactions completed in the quarter.

In addition to these financial results, Medtronic will host a video webcast on February 17, 2026, at 8:00 a.m. EST to discuss its business performance with investors and analysts. This webcast will be accessible through the company’s investor relations website.

Medtronic, headquartered in Galway, Ireland, aims to tackle the most pressing health challenges worldwide with its innovative technologies. The company employs over 95,000 individuals and offers solutions addressing 70 health conditions, including cardiac devices, surgical robotics, and patient monitoring systems.

For more information about Medtronic, visit their official website or follow them on LinkedIn.